In 2013, a personal care product company awarded Professor Pattarkine $47,400 to research herbal oil-based antimicrobial nanoparticles. The research, which employed an undergraduate student, identified an improved alternative to the antimicrobial agent used by the company.

In 2016, Pattarkine received two Presidential Research grants from HU. One of the grants has funded a ‘Development of Novel Paper-Based Diagnostic Devices’ project, dedicated to researching innovative and low-cost optical biosensors for pharmaceutical and environmental applications, such as diagnosing pesticides in water samples and testing for drug potency. This grant was submitted in collaboration with Conductive Technologies Inc, a Biosensor company from York, Pennsylvania which has partnered and supported the HU Nanobiotechnology program for past several years

The other PRG grant dedicated to establish ‘HU Center for Regenerative Medicine,’ has two aims- the development of hydrogels optimized for cell regeneration of vertebral discs and the creation of a 3D-printed prototype for contoured skin grafts. This grant is in collaboration with fellow HU Professor Glenn Mitchell, an engineer and retired army Emergency Physician. This prototype will provide innovative, cost-effective, and expedited treatment options for rapid production of contour-matched skin grafts used on severe burn patients.

Molecular Diagnostics- Dr. Doug Taylor’s research interests are in the field of Molecular Diagnostics. His research is focused on identifying the driver mechanisms underlying human disease. He has primarily investigated proteomic and genomic aberrations that lead to the development of cancer, adverse pregnancy outcomes, transplantation rejection, and neurological disease. He has specifically focused on these aberrations that can alter the host immunological responses to the affected tissue. By understanding these molecular events and their timing, his research has developed diagnostic assays specifically targeting these alterations for use in screening of disease, for use as a companion diagnostic for the pharmaceutical industry, monitoring of individuals at high risk of developing cancer, defining therapeutic targets for personized therapy, real-time assessment of therapeutic efficiency and the early detection of therapeutic failures. Further, by understanding specific molecular alterations that are essential for disease development, new therapeutics can be developed targeting those aberrations. These new therapeutics can include vaccines targeting commonly altered proteins or using the host’s own immune recognition to prophylactically eradicate diseased cells expressing these genetic and protein alterations.  Based on Dr. Taylor’s findings, it is currently possible to understand events associated with therapeutic success and failures and to stratify patients most likely to respond to the therapy.